KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Gilead Sciences (GILD) EBT Margin (2016 - 2025)

Gilead Sciences' EBT Margin history spans 17 years, with the latest figure at 26.22% for Q4 2025.

  • For Q4 2025, EBT Margin fell 241.0% year-over-year to 26.22%; the TTM value through Dec 2025 reached 33.27%, up 3087.0%, while the annual FY2025 figure was 33.27%, 3087.0% up from the prior year.
  • EBT Margin reached 26.22% in Q4 2025 per GILD's latest filing, down from 46.87% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 46.87% in Q3 2025 to a low of 67.1% in Q1 2024.
  • Average EBT Margin over 5 years is 22.07%, with a median of 26.85% recorded in 2022.
  • Peak YoY movement for EBT Margin: plummeted -8756bps in 2024, then soared 9183bps in 2025.
  • A 5-year view of EBT Margin shows it stood at 10.48% in 2021, then surged by 162bps to 27.49% in 2022, then dropped by -15bps to 23.24% in 2023, then grew by 23bps to 28.63% in 2024, then fell by -8bps to 26.22% in 2025.
  • Per Business Quant, the three most recent readings for GILD's EBT Margin are 26.22% (Q4 2025), 46.87% (Q3 2025), and 34.3% (Q2 2025).